{"id":"https://openalex.org/W2914154668","doi":"https://doi.org/10.1182/blood-2018-99-113042","title":"Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma","display_name":"Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2914154668","doi":"https://doi.org/10.1182/blood-2018-99-113042","mag":"2914154668"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-113042","doi":"https://doi.org/10.1182/blood-2018-99-113042","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-113042","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030964833","display_name":"Mary H. Young","orcid":"https://orcid.org/0000-0003-2921-6107","observed_orcids":["https://orcid.org/0000-0003-2921-6107"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Mary H Young","raw_affiliation_strings":["Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037952009","display_name":"Sam A Danziger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Sam A Danziger","raw_affiliation_strings":["Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Alison Fitch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Alison Fitch","raw_affiliation_strings":["Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011438142","display_name":"Frank Schmitz","orcid":"https://orcid.org/0000-0002-9090-0277","observed_orcids":["https://orcid.org/0000-0002-9090-0277"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Frank Schmitz","raw_affiliation_strings":["Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053392706","display_name":"Jake Gockley","orcid":"https://orcid.org/0000-0001-7993-5308","observed_orcids":["https://orcid.org/0000-0001-7993-5308"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jake Gockley","raw_affiliation_strings":["Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065697770","display_name":"Mark T. McConnell","orcid":"https://orcid.org/0000-0003-0978-2291","observed_orcids":["https://orcid.org/0000-0003-0978-2291"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Mark McConnell","raw_affiliation_strings":["Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087598092","display_name":"David J. Reiss","orcid":"https://orcid.org/0000-0001-5392-3034","observed_orcids":["https://orcid.org/0000-0001-5392-3034"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"David Reiss","raw_affiliation_strings":["Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013364487","display_name":"Wilbert B. Copeland","orcid":"https://orcid.org/0000-0002-9616-6341","observed_orcids":["https://orcid.org/0000-0002-9616-6341"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Wilbert B. Copeland","raw_affiliation_strings":["Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039175910","display_name":"Sadie Johnson","orcid":"https://orcid.org/0000-0001-5250-9835","observed_orcids":["https://orcid.org/0000-0001-5250-9835"]},"institutions":[{"id":"https://openalex.org/I2799656382","display_name":"University of Arkansas Medical Center","ror":"https://ror.org/005k4dn45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799656382"]},{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah K Johnson","raw_affiliation_strings":["Myeloma Institute, UAMS, Little Rock, AR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute, UAMS, Little Rock, AR","institution_ids":["https://openalex.org/I2799656382","https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076815798","display_name":"Katie Newhall","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Katie Newhall","raw_affiliation_strings":["Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019520048","display_name":"Robert Mark Hershberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert Hershberg","raw_affiliation_strings":["Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078587992","display_name":"Teri Foy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Teri Foy","raw_affiliation_strings":["Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006116532","display_name":"Alexander V. Ratushny","orcid":"https://orcid.org/0000-0002-1701-4084","observed_orcids":["https://orcid.org/0000-0002-1701-4084"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Alexander Ratushny","raw_affiliation_strings":["Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042516164","display_name":"Brian A. Walker","orcid":"https://orcid.org/0000-0002-8615-6254","observed_orcids":["https://orcid.org/0000-0002-8615-6254"]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian A Walker","raw_affiliation_strings":["Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR","institution_ids":["https://openalex.org/I79620101"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026255927","display_name":"Andrew Dervan","orcid":"https://orcid.org/0000-0002-6482-8654","observed_orcids":["https://orcid.org/0000-0002-6482-8654"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Andrew Dervan","raw_affiliation_strings":["Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immuno-Oncology Thematic Center of Excellence, Celgene Corporation, Seattle, WA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100632493","display_name":"Gareth John Morgan","orcid":"https://orcid.org/0000-0002-4271-6360","observed_orcids":["https://orcid.org/0000-0002-4271-6360","https://orcid.org/0000-0002-1275-2010","https://orcid.org/0000-0001-7073-2723"]},"institutions":[{"id":"https://openalex.org/I79620101","display_name":"University of Arkansas for Medical Sciences","ror":"https://ror.org/00xcryt71","country_code":"US","type":"education","lineage":["https://openalex.org/I79620101"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gareth Morgan","raw_affiliation_strings":["University of Arkansas for Medical Sciences, Little Rock, AR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Arkansas for Medical Sciences, Little Rock, AR","institution_ids":["https://openalex.org/I79620101"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5006116532","https://openalex.org/A5011438142","https://openalex.org/A5013364487","https://openalex.org/A5019520048","https://openalex.org/A5026255927","https://openalex.org/A5030964833","https://openalex.org/A5037952009","https://openalex.org/A5053392706","https://openalex.org/A5065697770","https://openalex.org/A5076815798","https://openalex.org/A5078587992","https://openalex.org/A5087598092"],"corresponding_institution_ids":["https://openalex.org/I4387155837"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"243","last_page":"243"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/bone-marrow-microenvironment","display_name":"bone marrow microenvironment","score":0.9929999709129333},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.8690000176429749},{"id":"https://openalex.org/keywords/monoclonal-gammopathy-of-undetermined-significance","display_name":"monoclonal gammopathy of undetermined significance","score":0.9869999885559082},{"id":"https://openalex.org/keywords/smoldering-multiple-myeloma","display_name":"smoldering multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8949999809265137},{"id":"https://openalex.org/keywords/cd4-t-cell-loss","display_name":"CD4+ T cell decline","score":0.7929999828338623},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.5600000023841858},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.6069999933242798},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.7639999985694885},{"id":"https://openalex.org/keywords/tumor-infiltrating-macrophages","display_name":"tumor-infiltrating macrophages","score":0.6209999918937683},{"id":"https://openalex.org/keywords/tumor-associated-neutrophils","display_name":"tumor-associated neutrophils","score":0.5830000042915344},{"id":"https://openalex.org/keywords/tumor-associated-b-cells","display_name":"tumor-associated B cells","score":0.44699999690055847},{"id":"https://openalex.org/keywords/tumor-associated-t-cells","display_name":"tumor-associated T cells","score":0.4309999942779541},{"id":"https://openalex.org/keywords/immunotherapy-targets","display_name":"immunotherapy targets","score":0.5730000138282776},{"id":"https://openalex.org/keywords/mass-cytometry","display_name":"mass cytometry","score":0.5699999928474426}],"concepts":[{"id":"https://openalex.org/C2777250017","wikidata":"https://www.wikidata.org/wiki/Q458138","display_name":"Monoclonal gammopathy of undetermined significance","level":5,"score":0.6999549269676208},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6800583004951477},{"id":"https://openalex.org/C2778015335","wikidata":"https://www.wikidata.org/wiki/Q17051163","display_name":"Mass cytometry","level":4,"score":0.6032596230506897},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.5779778957366943},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.525974690914154},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5135179162025452},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.489881694316864},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46520668268203735},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4518706798553467},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3303174078464508},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3143211603164673},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.27645814418792725},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.21156251430511475},{"id":"https://openalex.org/C127716648","wikidata":"https://www.wikidata.org/wiki/Q104053","display_name":"Phenotype","level":3,"score":0.1605989933013916},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09178578853607178},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-113042","doi":"https://doi.org/10.1182/blood-2018-99-113042","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-113042","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3212765489","https://openalex.org/W4414901463","https://openalex.org/W4285600990","https://openalex.org/W2980475309","https://openalex.org/W2985817614","https://openalex.org/W4405039187","https://openalex.org/W4413290326","https://openalex.org/W4414302809","https://openalex.org/W4378212662","https://openalex.org/W4292133689"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"The":[2,320],"multistep":[3],"progression":[4,109,382,560],"of":[5,19,30,78,135,138,168,177,187,222,254,260,266,272,310,322,373,394,402,477,515,541,563,579],"multiple":[6,143,148,153],"myeloma":[7,144,149,154,449,585],"from":[8,89,160,383,412,532],"a":[9,14,23,75,191,362,380,419,508,555,639],"normal":[10,270],"plasma":[11,250],"cell":[12,314,317,354,358,397,405,465,471,495,624,635],"to":[13,26,47,53,59,73,93,99,113,184,235,295,392,553,558,575,598],"system":[15],"with":[16,106,284,301,451,565,614,618],"the":[17,28,31,79,87,132,174,185,248,263,308,325,329,431,448,452,478,537,559,577,580,584,602,605],"features":[18,306],"invasive":[20],"cancer":[21],"provides":[22],"unique":[24],"opportunity":[25],"understand":[27,101,131],"co-evolution":[29],"malignant":[32],"clone":[33],"within":[34],"its":[35],"microenvironment.":[36],"Understanding":[37],"these":[38,469,542,634],"changes":[39,85,294],"is":[40,257,280,341,551,596],"becoming":[41],"increasingly":[42],"important":[43,342,597],"as":[44,110,112,409,430,473,481],"we":[45,68,156,172,198,489,506,572,592,611],"attempt":[46],"design":[48],"early":[49],"intervention":[50],"strategies":[51],"and":[52,61,82,119,151,180,207,213,274,290,315,332,352,367,375,389,399,406,454,486,499,539,561,568,608,631],"precisely":[54],"leverage":[55],"emerging":[56],"immunotherapeutic":[57],"modalities":[58],"prevent":[60],"treat":[62],"disease":[63,108,182,482],"progression.":[64],"In":[65,195,277,371,417],"this":[66,196,589],"work,":[67],"used":[69,199],"mass":[70,164],"cytometry":[71,165],"(CyTOF)":[72],"generate":[74,114],"high-resolution":[76],"map":[77],"BM":[80,158,175,186],"microenvironment":[81,298,480,582],"how":[83],"it":[84,344,595],"during":[86,546],"transition":[88],"health":[90],"through":[91],"pre-malignancy":[92],"disease.":[94],"This":[95,335],"approach":[96],"allows":[97],"us":[98],"both":[100,286,365,403],"microenvironmental":[102],"patterns":[103],"that":[104,122,239,292,518,544,594,627],"correlate":[105,613],"rapid":[107],"well":[111],"new":[115],"hypotheses":[116],"about":[117],"permissive":[118],"protective":[120],"immune-phenotypes":[121],"might":[123],"reveal":[124,536],"novel":[125],"immunologic":[126,133],"drug":[127],"targets.":[128],"Methods":[129],"To":[130],"characteristics":[134],"monoclonal":[136],"gammopathy":[137],"undetermined":[139],"significance":[140],"(MGUS),":[141],"smoldering":[142],"(SMM),":[145],"newly":[146,302],"diagnosed":[147,303],"(NDMM)":[150],"relapsed-refractory":[152],"(RRMM),":[155],"profiled":[157],"aspirates":[159],"79":[161],"patients":[162,268,285,564],"using":[163,190],"by":[166,219,233,462],"time":[167],"flight":[169],"(CyTOF).":[170],"Furthermore,":[171],"compared":[173],"compartment":[176,265],"pre-malignant,":[178],"malignant,":[179],"relapsed":[181],"states":[183],"healthy":[188,386,413],"donors":[189],"37-marker":[192],"pan-immune":[193],"panel.":[194],"panel,":[197],"antibodies":[200],"against":[201],"several":[202],"immune":[203,261,264,297,353,479,581],"lineages,":[204],"tumor":[205,249],"antigens,":[206],"functional":[208],"surface":[209],"markers,":[210],"including":[211,497],"co-stimulatory":[212],"co-inhibitory":[214],"receptors.":[215],"Cell":[216],"clusters":[217],"defined":[218],"Citrus":[220],"analysis":[221,423,591],"CyTOF":[223,445],"data":[224],"were":[225],"combined":[226],"into":[227,437],"an":[228,512],"evolutionarily":[229],"optimized":[230],"decision":[231],"tree":[232],"evtree":[234],"identify":[236],"cluster":[237],"interactions":[238],"strongly":[240],"partition":[241],"patient":[242],"samples.":[243],"Results":[244],"During":[245],"MGUS,":[246,566],"when":[247],"cells":[251,340,517,543],"are":[252,519,628],"<10%":[253],"BM,":[255],"there":[256,279,360,378],"little":[258],"evidence":[259],"dysregulation;":[262],"MGUS":[267],"contains":[269],"numbers":[271],"innate":[273],"adaptive":[275],"populations.":[276,334],"SMM,":[278,567],"considerably":[281],"more":[282,299],"heterogeneity,":[283],"resembling":[287,385],"MGUS/healthy":[288],"individuals":[289],"those":[291],"had":[293],"their":[296],"consistent":[300],"patients.":[304],"These":[305],"include":[307],"loss":[309,321,363,393,401,492],"specific":[311],"CD4":[312,323,338,390,407,426,456,606],"T":[313,339,349,621,623],"B":[316,357,369,388,396,404,464,494,501],"subsets":[318,408],"(FDR<0.1).":[319],"was":[324,361,379],"most":[326],"pronounced":[327],"in":[328,337,364,493,504,511,604],"central":[330],"memory":[331,368,428,458,498,607],"effector":[333,427,457,609],"reduction":[336],"because":[343],"diminishes":[345],"help":[346],"for":[347,434],"CD8":[348],"cell-mediated":[350],"killing":[351],"maturation.":[355],"Among":[356],"subsets,":[359,398,496],"mature":[366],"cells.":[370,502,528],"comparison":[372],"SMM":[374],"NDMM":[376,485],"samples,":[377,488],"clear":[381],"samples":[384,410,436,534],"(normal":[387],"subsets),":[391],"only":[395],"finally,":[400],"diverged":[411],"controls":[414],"(Figure":[415],"1).":[416],"addition,":[418],"supervised":[420],"machine":[421],"learning":[422],"(evtree)":[424],"identified":[425],"abundance":[429,466],"top":[432],"node":[433],"partitioning":[435],"two":[438,470],"distinct":[439],"subtypes":[440,459],"based":[441],"on":[442,588],"all":[443],"available":[444],"markers":[446],"across":[447,583],"continuum,":[450],"high":[453],"low":[455],"further":[460,599],"subdivided":[461],"pre-B/immature":[463],"(p=0.01),":[467],"supporting":[468],"types":[472,636],"being":[474],"robust":[475],"discriminators":[476],"evolves.":[483],"Between":[484],"RRMM":[487,505],"observed":[490,507],"heterogeneous":[491],"na\u00efve":[500],"Interestingly,":[503],"strong":[509],"increase":[510,545],"unidentified":[513],"population":[514],"CD45-":[516],"quiescent":[520],"(FDR<0.1),":[521],"which":[522],"may":[523,535],"be":[524,554],"stem":[525],"or":[526,622],"stromal":[527],"Available":[529],"RNA":[530],"sequencing":[531],"matching":[533],"lineage":[538],"function":[540],"relapse.":[547],"Conclusions":[548],"Immune":[549],"dysregulation":[550],"thought":[552],"major":[556],"contributor":[557],"outcome":[562],"MM.":[569],"Using":[570],"CyTOF,":[571],"have":[573],"begun":[574],"benchmark":[576],"content":[578],"continuum.":[586],"Based":[587],"cross-sectional":[590],"hypothesize":[593],"interrogate":[600],"whether":[601,632],"losses":[603],"populations":[610],"described":[612],"outcomes":[615],"after":[616],"therapy":[617],"either":[619],"CAR":[620],"engager":[625],"trials":[626],"currently":[629],"ongoing,":[630],"reconstituting":[633],"could":[637],"provide":[638],"meaningful":[640],"treatment":[641],"strategy.":[642],"Disclosures":[643],"Young:":[644],"Celgene":[645],"Corporation:":[646,651,656,661,666,669,672,677,682,687,695,700,705],"Employment,":[647,652,657,662,673,678,683,688,696,701,706],"Equity":[648,653,658,663,674,679,684,689,697,702,707],"Ownership.":[649,654,659,664,675,680,685,698,703,708],"Danziger:Celgene":[650],"Fitch:Celgene":[655],"Schmitz:Celgene":[660],"Gockley:Celgene":[665],"Employment.":[667,670],"McConnell:Celgene":[668],"Reiss:Celgene":[671],"Copeland:Celgene":[676],"Newhall:Celgene":[681],"Hershberg:Celgene":[686],"Ownership,":[690],"Patents":[691],"&":[692],"Royalties.":[693],"Foy:Celgene":[694],"Ratushny:Celgene":[699],"Dervan:Celgene":[704],"Morgan:Takeda:":[709],"Consultancy,":[710,716,722],"Honoraria;":[711],"Janssen:":[712],"Research":[713,718],"Funding;":[714,719],"Celgene:":[715],"Honoraria,":[717],"Bristol-Myers":[720],"Squibb:":[721],"Honoraria.":[723]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-02-21T00:00:00"}